Search Results for "Contraceptives"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Contraceptives. Results 81 to 90 of 121 total matches.
Expanded Table: Some Conventional DMARDs for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
Persons taking the drug should use
effective contraception while taking
methotrexate and for at least 6 ...
View Expanded Table: Some Conventional DMARDs for Rheumatoid Arthritis
Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis (online only)
The Medical Letter on Drugs and Therapeutics • Nov 15, 2021 (Issue 1637)
women should
generally be avoided
Women who could become
pregnant should use effective
contraception ...
View Expanded Table: Some Biologic Drugs and JAK Inhibitors for Rheumatoid Arthritis
Treatment of Onychomycosis
The Medical Letter on Drugs and Therapeutics • Oct 18, 2021 (Issue 1635)
Griseofulvin decreases serum concentrations of
warfarin, cyclosporine, salicylates, and oral contraceptives ...
Onychomycosis is caused most commonly by
Trichophyton rubrum or T. mentagrophytes. About
10% of all persons worldwide and 40% of those ≥60
years old are believed to have the disease. Risk
factors include older age, diabetes, poor peripheral
circulation, smoking, HIV infection, psoriasis, and
immunosuppression. Left untreated, onychomycosis
can cause nail plate destruction, ingrown nails, and
(particularly in patients with diabetes) secondary
infections. Guidelines on treatment of onychomycosis
have been published.
Ozanimod (Zeposia) for Ulcerative Colitis
The Medical Letter on Drugs and Therapeutics • Sep 20, 2021 (Issue 1633)
use adequate
contraception during treatment with ozanimod and for 3
months after stopping the drug ...
The oral sphingosine 1-phosphate (S1P) receptor
modulator ozanimod (Zeposia – Bristol Myers Squibb)
has been approved by the FDA for treatment of adults
with moderately to severely active ulcerative colitis. It
is the first S1P receptor modulator to be approved for
treatment of ulcerative colitis. Ozanimod was approved
in March 2020 for use in adults with relapsing forms of
multiple sclerosis.
Myfembree for Fibroid-Associated Heavy Menstrual Bleeding
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
by uterine fibroids.2 A
combination contraceptive (oral, patch, or vaginal
ring) or a levonorgestrel ...
Myfembree (Myovant/Pfizer), an oral fixed-dose
combination of the gonadotropin-releasing hormone
(GnRH) receptor antagonist relugolix, the estrogen
estradiol, and the progestin norethindrone acetate,
has been approved by the FDA for management of
heavy menstrual bleeding associated with uterine
leiomyomas (fibroids) in premenopausal women. It is
the second product to be approved in the US for this
indication; Oriahnn, which contains the GnRH receptor
antagonist elagolix in combination with estradiol and
norethindrone acetate, was approved earlier. Relugolix
was approved for...
Ponesimod (Ponvory) for Multiple Sclerosis
The Medical Letter on Drugs and Therapeutics • Aug 09, 2021 (Issue 1630)
malformations. Women of childbearing potential should
use effective contraception while taking ponesimod ...
The FDA has approved ponesimod (Ponvory –
Janssen), a sphingosine 1-phosphate (S1P) receptor
modulator, for treatment of adults with relapsing forms
of multiple sclerosis (MS), including clinically isolated
syndrome (initial neurological episode), relapsing-remitting
disease, and active secondary progressive
MS (SPMS). Ponesimod is the fourth oral S1P receptor
modulator to be approved in the US for once-daily
treatment of relapsing forms of MS; ozanimod
(Zeposia) and siponimod (Mayzent) are also approved
for use in adults, and fingolimod (Gilenya) is indicated
for use in patients...
Estetrol/Drospirenone (Nextstellis) - A New Combination Oral Contraceptive
The Medical Letter on Drugs and Therapeutics • Jun 28, 2021 (Issue 1627)
Estetrol/Drospirenone (Nextstellis) - A New Combination Oral Contraceptive ...
The FDA has approved a combination oral
contraceptive containing the estrogen estetrol and the
progestin drospirenone (Nextstellis – Mithra/Mayne).
Estetrol is the first new estrogen to become available
in the US in 50 years. Drospirenone is available alone
(Slynd) and in combinations with the estrogen ethinyl
estradiol for prevention of pregnancy.
Drugs for Chronic Heart Failure
The Medical Letter on Drugs and Therapeutics • Jun 14, 2021 (Issue 1626)
studies with ivabradine; women of
childbearing age should use effective contraception
while taking ...
Among patients with chronic heart failure, those with
a left ventricular ejection fraction (LVEF) ≤40% are
considered to have heart failure with reduced ejection
fraction (HFrEF). Patients with a LVEF ≥50% are
considered to have heart failure with preserved ejection
fraction (HFpEF). Those with a LVEF of 41-49% are an
intermediate group more similar to patients with HFpEF.
Teprotumumab (Tepezza) for Thyroid Eye Disease
The Medical Letter on Drugs and Therapeutics • May 31, 2021 (Issue 1625)
.
Women of childbearing potential should use effective
contraception before starting treatment, during ...
Teprotumumab-trbw (Tepezza - Horizon), an insulin-like
growth factor-1 receptor (IGF-1R) inhibitor, has
been approved by the FDA for IV treatment of thyroid
eye disease. It is the first drug to be approved in the US
for this indication.
Evinacumab (Evkeeza) for Homozygous Familial Hypercholesterolemia
The Medical Letter on Drugs and Therapeutics • May 03, 2021 (Issue 1623)
a pregnancy test before starting evinacumab
and should use contraception during treatment and
for at least 5 ...
The FDA has approved evinacumab-dgnb (Evkeeza –
Regeneron), an angiopoietin-like 3 (ANGPTL3) inhibitor,
for adjunctive IV treatment of homozygous familial
hypercholesterolemia (HoFH) in patients ≥12 years
old. Evinacumab is the first ANGPTL3 inhibitor to be
approved in the US.